证券日报网讯2月3日，鹭燕医药（002788）在互动平台回答投资者提问时表示，公司严格按规定及时披 露重大信息，公司重大信息请关注公司公告。 ...

当天雪球就赶紧行动，早中晚发了三批公告，一共有22个大V账号被永久封禁，都是长期推荐股票，拥 有众多粉丝的大号。大资金割韭菜，又当大V收割股民的会费，又让股民接盘买股，简直是要把股民榨 干。 文丨金融八卦女特约作者：兴华 · · · 最近，各路股票大V瑟瑟发抖！ 1月19日刚开市，监管就给一个股票大V下了8300万元的处罚书。 同时，最高人民检察院也提出，会同中国证监会深化资本市场法治建设，完善证券检察派驻工作机制， 从严惩治财务造假、操纵市场等证券犯罪，维护资本市场安全。 当天雪球就赶紧行动，早中晚发了三批公告，一共有22个大V账号被永久封禁，都是长期推荐股票，拥 有众多粉丝的大号。 随后蚂蚁、抖音、腾讯等大平台也都宣布，平台除了日常监测和处置，近期有对违规内容的重点打击行 动。 大资金割韭菜，又当大V收割股民的会费，又让股民接盘买股，简直是要把股民榨干。 1月19日，浙江证监局发布行政处罚决定书，认定金永荣构成"抢帽子操纵"证券市场行为，对其罚没合 计超8300万元，并采取3年证券市场禁入措施。 这个金永荣，在雪球上叫"金浤"，有13万粉丝。 "金浤"从2019年就开始更新文章，最开始分享的都是作为一个普 ...

Core Viewpoint - The A-share market for pharmaceutical retail stocks experienced a collective rise, driven by new government measures aimed at enhancing pharmaceutical services and encouraging retail drug sales [1] Group 1: Market Performance - Pharmaceutical retail stocks such as Renmin Tongtai and Yifeng Pharmacy hit the daily limit up, while Luyuan Pharmaceutical rose over 7%, Daclin increased over 6%, and Jiuzhoutong gained over 5% [1] - Other notable performers included Zhongyao Holdings, Yaoyigou, Haiwang Biological, Hefuchina, and Shuyupingmin, all rising over 4% [1] Group 2: Government Measures - The Ministry of Commerce and nine other departments issued a document proposing improvements in pharmaceutical services, enhancing pharmacy service capabilities, and promoting prescription circulation to improve the purchasing experience [1] - Measures include optimizing outpatient service coordination for designated retail pharmacies and encouraging retail drug companies to participate in centralized drug procurement [1] - The government is promoting horizontal mergers and acquisitions among retail drug companies and encouraging the sale of innovative drugs and reference preparations through retail channels [1] - There is an emphasis on encouraging e-pharmacy platforms to open data interfaces and strengthen the monitoring of price linkages between online and offline drug retail prices and provincial procurement platform prices [1]

Group 1 - The core viewpoint of the article highlights a collective rise in A-share pharmaceutical commercial stocks, driven by government initiatives to enhance pharmaceutical services and retail drug sales [1] - The Ministry of Commerce and nine other departments issued a document proposing measures to improve pharmaceutical services, enhance pharmacy service capabilities, and promote prescription circulation to improve the purchasing experience [1] - The document encourages pharmaceutical retail companies to engage in horizontal mergers and acquisitions, and to innovate in drug sales channels, including the sale of innovative drugs and reference preparations through retail pharmacies [1] Group 2 - Notable stock performances include: - Renmin Tongtai (人民同泰) with a rise of 10.04% and a total market value of 72.43 billion [2] - Yifeng Pharmacy (益丰药房) increasing by 10.02% with a market cap of 301 billion [2] - Luyuan Pharmaceutical (鹭燕医药) up by 7.76% with a market value of 70.13 billion [2] - Dacelin (大参林) rising by 6.63% with a market cap of 242 billion [2] - Jiuzhoutong (九州通) increasing by 5.27% with a market value of 282 billion [2] - Other companies showing significant gains include Zhongyao Holdings (重药控股) up by 4.89%, Yaoyigou (药易购) up by 4.42%, and Haiwang Biological (海王生物) up by 4.41% [2]

Market Overview - The pharmaceutical commercial sector experienced a decline of 0.37% on January 21, with Luyuan Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 4116.94, up 0.08%, while the Shenzhen Component Index closed at 14255.12, up 0.7% [1] Stock Performance - Notable gainers in the pharmaceutical commercial sector included: - Guofa Co., Ltd. (600538) with a closing price of 7.04, up 2.47% and a trading volume of 179,300 shares [1] - Jianfa Zhixin (301584) closed at 31.02, up 1.54% with a trading volume of 45,500 shares [1] - Yaoyigou (300937) closed at 35.56, up 1.40% with a trading volume of 32,800 shares [1] - Other stocks with minor gains included Dacilin (603233), Baiyang Pharmaceutical (301015), and Rundar Medical (603108) [1] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 254 million yuan from institutional investors, while retail investors had a net inflow of 313 million yuan [2] - The top stocks by net inflow from retail investors included: - Zhejiang Zhenyuan (000705) with a net inflow of 1.67 million yuan [3] - Rundar Medical (603108) with a net outflow of 50.04 million yuan [3] Individual Stock Analysis - Rundar Medical (603108) had a net inflow of 29.30 million yuan from institutional investors, but a significant outflow from retail investors [3] - Guofa Co., Ltd. (600538) experienced a net inflow of 8.32 million yuan from institutional investors, while retail investors showed a minor inflow [3] - Baiyang Pharmaceutical (301015) had a net inflow of 8.21 million yuan from institutional investors, but a net outflow from retail investors [3]

证券代码：002788 证券简称：鹭燕医药 公告编号：2026-003 鹭燕医药股份有限公司 关于"鹭燕现代中药生产项目"建设情况的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 鹭燕医药股份有限公司（以下简称"公司"）于 2020 年 11 月 16 日召开第五届董事会第 二次会议，审议通过了《关于向亳州市中药饮片厂增加投资及建设现代中药生产项目的议案》， 同意公司以子公司亳州市中药饮片厂为建设主体，在亳州市谯城经济开发区内建设"鹭燕现 代中药生产项目"。（具体内容详见《关于向亳州市中药饮片厂增加投资及建设现代中药生产 项目的公告》，公告编号：2020-079）。 法定代表人：朱明国 质量授权人：毛安伟 生产地址和生产范围： 亳州市药都路 1888 号：中药饮片（含毒性饮片，直接口服饮片，净制、切制、蒸制、 企业负责人：张涛 质量负责人：毛安伟 生产负责人：陈仲连 煮制、炒制、炙制、制炭、燀制、煅制）注：毒性饮片（净制、切制、煮制、炙制） 亳州市药都路 2999 号：中药饮片（净制、切制、蒸制、煮制、炖制、炒制、炙制、煅 制、制炭、煨制、燀制、水飞 ...

Core Viewpoint - The company is actively promoting the construction of the "Luyan Modern Traditional Chinese Medicine Production Project" in Bozhou, which has successfully completed the first phase of construction, including various production and office facilities [1] Group 1: Project Development - The project is located at No. 2999 Yaodu Road, Bozhou City, and has a total construction area of approximately 180,000 square meters [1] - The first phase includes the completion of facilities such as a general Chinese medicine processing workshop, toxic processing workshop, auxiliary workshop, raw material warehouse, finished product warehouse, comprehensive office building, and academic exchange center [1] Group 2: Regulatory Approval - The Anhui Provincial Drug Administration has approved the expansion of the production scope and address for the Bozhou Chinese Medicine Processing Plant [1] - The Bozhou Chinese Medicine Processing Plant obtained a new "Drug Production License" on January 21, 2026 [1]

鹭燕医药公告称，2020年11月公司同意以子公司亳州市中药饮片厂为主体，在亳州建设"鹭燕现代中药 生产项目"。截至目前，项目一期完成生产及办公设施建设，建筑面积约18万平方米。近日，安徽省药 监局审批同意亳州市中药饮片厂新增生产范围和地址，该厂于1月21日取得新《药品生产许可证》。项 目一期完成可为公司中药饮片产能提供保障，助力拓展市场、增强竞争力。 ...

Market Overview - The pharmaceutical commercial sector experienced a decline of 0.48% on January 20, with Luyuan Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 4113.65, down 0.01%, while the Shenzhen Component Index closed at 14155.63, down 0.97% [1] Stock Performance - Notable gainers in the pharmaceutical sector included: - Guofa Co., Ltd. (600538) with a closing price of 6.87, up 3.46% and a trading volume of 245,400 shares, totaling 168 million yuan [1] - Huaren Health (301408) closed at 22.08, up 1.38% with a trading volume of 317,600 shares, totaling 700 million yuan [1] - Conversely, significant decliners included: - Jianghe Pharmaceutical (002788) with a closing price of 16.64, down 6.04% and a trading volume of 872,500 shares, totaling 1.465 billion yuan [2] - Yingte Group (000411) closed at 13.84, down 2.40% with a trading volume of 230,300 shares, totaling 316 million yuan [2] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 497 million yuan from institutional investors and a net outflow of 109 million yuan from speculative funds, while retail investors had a net inflow of 607 million yuan [2] - Key stocks with notable capital flows included: - Huaren Health (301408) with a net inflow of 46.16 million yuan from institutional investors, but a net outflow of 48.48 million yuan from retail investors [3] - Yifeng Pharmacy (603939) had a net inflow of 21.74 million yuan from institutional investors, but also saw a net outflow of 1.63 million yuan from retail investors [3]

截至2026年1月16日收盘，鹭燕医药(002788)报收于19.68元，下跌10.01%，已连续跌停2天，换手率 1.35%，成交量5.17万手，成交额1.02亿元。 当日关注点 投资者： 公司旗下的康源爱心（广州）科技有限公司开发的四款康源AI心电设备参加了第92届中国国 际医疗器械博览会，目前相关产品上市了吗？ 董秘： 公司重大信息请查阅公司公告。 投资者： 尊敬的董秘您好，我代表广大持有贵公司股票的散户冒昧的问一句，贵公司鹭燕医药002788 是否属于ai医疗应用概念呢？ 交易信息汇总 鹭燕医药（002788）1月16日收盘报19.68元，跌停，当日成交516.62万元。该股已连续4日下跌，近5个 交易日中有3日跌幅超5%。前10个交易日主力资金累计净流出7.59亿元，期间股价累计下跌7.2%。 当日主力资金净流出2417.69万元，游资资金净流入27.16万元，散户资金净流入2390.53万元。 因连续三个交易日内跌幅偏离值累计达20%，鹭燕医药登上龙虎榜，为近5个交易日内第2次上榜。 公司公告汇总 鹭燕医药股份有限公司股票于2026年1月14日至1月16日连续三个交易日内收盘价格跌幅偏离值累计超过 ...